Ii-Key/antigenic epitope hybrid peptide vaccines

Details Ii-Key/antigenic epitope hybrid peptide vaccines Ii-Key/antigenic epitope hybrid peptide vaccines

2007-02-20

2007-02-20

Li, Q. Janice (Department: 1633)

Chemistry: molecular biology and microbiology

Vector, per se

C536S023100, C536S023400, C514S04400A

Reexamination Certificate

active

10253286

ABSTRACT:
Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4–16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

REFERENCES:
patent: 4650764 (1987-03-01), Temin et al.
patent: 4708871 (1987-11-01), Geysen
patent: 4797368 (1989-01-01), Carter et al.
patent: 5126132 (1992-06-01), Rosenberg
patent: 5194392 (1993-03-01), Geysen
patent: 5270170 (1993-12-01), Schatz et al.
patent: 5284935 (1994-02-01), Clark et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5539084 (1996-07-01), Geysen
patent: 5556762 (1996-09-01), Pinilla et al.
patent: 5559028 (1996-09-01), Humphreys
patent: 5595915 (1997-01-01), Geysen
patent: 5679527 (1997-10-01), Humphreys
patent: 5693522 (1997-12-01), Chada et al.
patent: 5747334 (1998-05-01), Kay et al.
patent: 5849586 (1998-12-01), Kriegler et al.
patent: 5856185 (1999-01-01), Gruber et al.
patent: 5856456 (1999-01-01), Whitlow et al.
patent: 5874077 (1999-02-01), Kriegler et al.
patent: 5874214 (1999-02-01), Nova et al.
patent: 5910300 (1999-06-01), Tournier et al.
patent: 5919639 (1999-07-01), Humphreys et al.
patent: 6120769 (2000-09-01), Gefter et al.
patent: 6432409 (2002-08-01), Humphreys et al.
US 5,382,513, 01/1995, Lam et al. (withdrawn)
Bowie et al, Science Mar. 1990; 247:1306-10.
Makrides et al, Protein Exp Pur. 1999; 17:183-202.
Eck et al, Phar Basis Ther 1995; 77-101.
Verma et al, Nat. Sep. 1997; 389:239-242.
Zink et al, Gene Ther Mol Biol Jan. 2001;6:1-24.
Robbins et al, Pharmcol Ther 1998;80:35-47.
Adams et al., Arzneimittelforschung 47: 1069-77 (1997).
Adams et al., Eur. J. Immunol. 25: 1693-702 (1995).
Castilleja et al., Mol. Cell Biochem. 217: 21-33 (2001).
Daibata et al., Mol. Immunol. 31: 255-60 (1994).
Disis et al., J. Clin. Oncol. 20: 2624-32 (2002).
Hess et al., Clin. Immunol. 101: 67-76 (2001).
Humphreys et al., Vaccine 18: 2693-7 (2000).
Kawakami et al., Proc. Natl. Acad. Sci. USA 91: 3515-9 (1994).
Kawakami et al., J. Exp. Med. 180: 347-52 (1994).
Kawakami et al., Proc. Natl. Acad. Sci. USA 91: 6458-6462 (1994).
Knutson et al., J. Clin. Invest. 107: 477-84 (2001).
Kuerer et al., J. Interleron Cytokine Res. 22: 583-92 (2002).
Lustgarten et al., Hum. Immunol. 52: 109-18 (1997).
Moudgil et al., J. Immunol. 163: 4232-7 (1999).
Rammensee et al., Immunogenetics 41: 178-228 (1995).
Texier et al., J. Immunol. 164: 3177-84 (2000).
Xu et al., Arzneimittelforschung 49: 791-9 (1999).

Affiliated with

Also associated with

Rating

Ii-Key/antigenic epitope hybrid peptide vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ii-Key/antigenic epitope hybrid peptide vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ii-Key/antigenic epitope hybrid peptide vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3870723